EARS News and Press, Auris Medical Holding AG From 04/08/21

Top Biotech Penny Stocks To Watch If you are looking to invest in penny stocks, there has never been a better time than now. By definition, the term “ penny stock ” refers to stocks that trade under $5. Thanks to this, the low cost provides an interesting entry opportu...

Gainers: Vericity (VERY) +76%.ORBCOMM (ORBC) +52%.Rice Acquisition (RICE) +37%.China Green Agriculture (CGA) +27%.Century Bancorp (CNBKA) +25%.PAR Technology (PAR) +25%.American Virtual Cloud Technologies (AVCT) +21%.180 Life Sciences (ATNF) +20%.Auris Medical (EARS) +18%....

Gainers: Auris Medical (EARS) +18%, Prometheus Biosciences (RXDX) +15%, Crinetics Pharmaceuticals (CRNX) +13%, Genprex (GNPX) +12%, Fortress Biotech (FBIO) +12%.Losers: Endo International (ENDP) -10%, Odonate Therapeutics (ODT) -9%, Otonomy (OTIC) ...

Hamilton, Bermuda, April 8, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that it will provide a busin...

Auris Medical Holding ([[EARS]] +8.7%) is surging on the news of a patent grant by the United States Patent and Trademark Office (USPTO).According to the USPTO database, the patent named ‘methods for the treatment of tinnitus induced by cochlear excitotoxicity,’ has been aw...

GameStop GME -14% after announces share offering, preliminary sales.ACADIA Pharmaceuticals ACAD -15% as FDA rejects Nuplazid label expansion.Uxin (UXIN) -9%.Sonoma Pharmaceuticals (SNOA) -9%.Auris Medical Holding (EARS) -4%.New Concept Energy (GBR) -6%.AeroCentury (ACY) -5...

Auris Medical (EARS) down 3% premarket after announcing FY 2020 results and business update.Total operating expenses were CHF5.3M compared to CHF7.3M for 2019.Net loss was CHF8.2M, or CHF1.36/share, compared to CHF6.6M or CHF2.28/share for prior year.Cash and equivalents at December...

Auris Medical (EARS): FY GAAP EPS of -CHF1.36.R&D expenses for 2020 were CHF2.9M, compared to CHF3.3M for 2019.Cash and cash equivalents of CHF11.3M.Shares are up 5% premarket.Press Release For further details see: Auris Medical reports FY 2020 results

Clinical evaluation of AM-301 nasal spray in allergen protection progressing Launch of AM-301 expected in selected markets towards the end of second quarter 2021 Phase 2 trial with AM-125 in acute vertigo expected to complete enrollment in third quarter 2021 Equity and cash po...

Hamilton, Bermuda, March 24, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that it will provide a busi...